Conference Coverage
Conference Coverage
In IDH-mutated AML, first-line IDH inhibitors plus chemo may boost remission
SAN DIEGO – Minimal residual disease and mutational clearance were seen in a significant proportion of patients.
Conference Coverage
Lower-dose rituximab may be enough in acquired TTP
SAN DIEGO – A lower dose of rituximab appears effective, but it still carries side effects.
Video
Model bests IPSS-R for predicting survival, risk for AML in myelodysplastic syndrome
Conference Coverage
TOURMALINE-MM3: Ixazomib improves PFS after myeloma transplant
SAN DIEGO – A leading investigator put the results in perspective with the currently approved lenalidomide, and the audience questions as to...
Video
JULIET: CAR T cells go the distance in r/r DLBCL
SAN DIEGO – Median overall survival among patients with complete responses to CAR-T cell therapy in the JULIET trial has not been reached.
Video
Beat AML trial delivers genomic results in 7 days
SAN DIEGO – The umbrella trial, sponsored by the Leukemia & Lymphoma Society, harnesses technology to speed genomic results that could...
Video
Gut bacteria influence HCT outcomes
SAN DIEGO – Gut microbiome diversity predicts overall survival after hematopoietic cell transplant.
Conference Coverage
JULIET: CAR T cells keep trucking against DLBCL
SAN DIEGO – Median overall survival for patients with complete responses to CAR T-cell therapy was not reached through 19 months of follow-up.
Conference Coverage
ELIANA update: Tisagenlecleucel responses durable in r/r B-cell ALL
SAN DIEGO – Among patients who had complete remissions, 66% were still in remission at 18 months, overall survival was 70%, and median overall...
Conference Coverage
Opioids appear safe for sickle cell pain
SAN DIEGO – For sickle cell patients, opioid-related mortality is essentially a “never” event.
